PATENT

IN THE COLTED TATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art Unit 1642

File No. of prior application: 4573.US.C5

Filed: May 14, 1997

For: MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN

Case No.: 4573.US.C6

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231, on:

January 10, 2002

Name of person signing this certificate: Kimberly A. Iorio

Signature:

STATEMENT OF MAILING OF PATENT APPLICATION UNDER 37 C.F.R. 1.6(e)

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231

Dear Sir:

I, Kimberly A. Iorio, an employee of Abbott Laboratories in the Patent and Trademark Department, attempted to mail the following documents, enclosed herein as Attachment A, via U.S. Express Mail addressed to the U.S. Patent and Trademark Office on November 19, 2001:

Utility Patent Application a continuation of prior application No. 08/856,155;

Fee Transmittal;

Copy of original Specification, Claims, and Abstract;

Copy of Drawings;

Copy of original Declaration and Power of Attorney;

Copy of Original Assignment;

Request for Three-Month Extension of Time, in duplicate;

Transmittal Letter; and

Two Return Receipt Postcards.

I was refused express mail service from the United States Postal Service due to government security measures, as more fully set forth in the November 16, 2001, U.S. Postal Service Memo entitled Temporary Suspension of Express Mail Service to Washington, DC ZIP Codes 202 through 205, enclosed herein as Attachment B.

Once advised that Express Mail to Washington, DC ZIP Codes 202 through 205 was suspended, I deposited the above-referenced documents along with the Suspension of Express Mail Memo with the U.S. Postal Service as First Class Mail addressed to the to

eieight date granter.

Lordon

James Princer

Serial No.: (not yet assigned) Attorney Docket No.: 4573.US.C5 Statement of Mailing Under 37 C.F.R. 1.6(e)

the U.S. Patent and Trademark Office, Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231-0001, enclosed herein as Attachment C.

To date, our office has not yet received verification from the U.S. Patent and Trademark Office of receipt of our above-named application. If you require additional evidence or information to determine that the above-referenced patent application was timely filed, please contact me at (847) 937-6369.

I hereby declare that all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the instant patent specification or any patent issuing therein.

Respectfully submitted,

Abbott Laboratories D-377, AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-3500 (847) 937-6369 (847) 938-2623 FAX



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art

Unit 1642

File No. of prior application: 4573.US.C5

Filed: May 14, 1997

For: MOUSE MONOCLONAL ANTIBODY (5 - 21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN

Case No.: 4573.US.C6

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231, on:

January 10, 2002

Name of person signing this certificate: Kimberly A. Iorio

Signatur

TRANSMITTAL LETTER

Assistant Commissioner for Patents Box Filing Date Washington D.C. 20231

Dear Sir:

Enclosed herewith is the Statement of Mailing of Patent Application Under 37 C.F.R. 1.6(e) Transmittal Letter for MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN.

Also enclosed is:

Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR 1.17 concerning this transaction, or to credit any overpayment, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES

Telephone: (847) 938-3137 Facsimile: (847) 938-2623

Respectfully submitted, J. C. Hunt, et al.

Dianne Casuto

Registration No. 40,943 Attorney for Applicants





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art

Unit 1642

File No. of prior application: 4573.US.C5

Filed:

For: MOUSE MONOCLONAL ANTIBODY (5 -21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN

Case No.: 4573.US.C6

Date: November 19, 2001

EXPRESS MAIL NO.: EL507386035US

Certificate of Mailing under 37 CFR §1.10:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231

on November 19, 2001

Name of person signing

this certificate: Kimberly A. Iorio

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington D.C. 20231

Dear Sir:

Enclosed herewith is the Utility Patent Application Transmittal Letter of Jeffrey C. Hunt, et al., for MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN.

Also enclosed are:

Fee Transmittal, in duplicate (1 Page)

Copy of Original Specification, Claims and Abstract (41 Pages)

Copy of Drawings/Figures (6 Pages)

Copy of Original Executed Declaration and Power of Attorney (2

Pages)

Copy of Original Assignment (1 Page)

Request for Three-Month Extension of Time, in duplicate

Two Return Receipt Postcards

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR 1.17 concerning this transaction, or to credit any overpayment, to Deposit Account No. 01-0025.

A duplicate copy of this sheet is enclosed.

Abbott Laboratories Dept. 377/AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-6050 Tel. No. (847) 938-3137 Fax No. (847) 938-2623

Respectfully submitted,

J.C. Hunt, et al.

Cheryl L. Becker Registration No. 35,441 Attorney for Applicant(s)



PTO/SB/17 (12/99)
Approved for use through 09/30/2000. OMB 0851-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2000

Patent fees are subject to annual revision.

Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

TOTAL AMOUNT OF PAYMENT (\$) 1,846.00

Complete if Known		
Application Number		
Filing Date		
First Named Inventor	Jeffrey C. Hunt	
Examiner Name	B. Brumback	
Group / Art Unit	1642	
Attorney Docket No.	4573.US.C6	

METHOD OF PAYMENT (check one)	FEE CALCULATION	(continued)			
1. X The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES Large Entity Small Entity				
Deposit	Fee Fee Fee Fee Fee Descrip Code (\$) Code (\$)	tion Fee Paid			
Account Number 01-0025	105 130 205 65 Surcharge - late filing fee	ir oath			
Deposit	127 50 227 25 Surcharge - late provisions cover sheet.	of filing fee or 0.00			
Account Name Abbott Laboratories	139 130 139 130 Non-English specification				
Charge Any Additional Fee Required	147 2,520 147 2,520 For filing a request for reex	amination			
0782 07 07 13 3 110 212 17	112 920° 112 920° Requesting publication of Examiner action	SIR prior to			
2. Payment Enclosed: Check Money Other	113 1,840° 113 1,840° Requesting publication of S Examiner action				
FEE CALCULATION	115 110 215 55 Extension for reply within f				
	116 380 216 190 Extension for reply within s				
1. BASIC FILING FEE Large Entity Small Entity	117 870 217 435 Extension for reply within t				
Fee Fee Fee Fee Description	118 1,360 218 680 Extension for reply within f				
0000 (p) 0000 (p)	128 1,850 228 925 Extension for reply within f	fih month			
101 690 201 345 Utility filing fee 740.00	119 300 219 150 Notice of Appeal				
107 480 207 240 Plant filing fee	120 300 220 150 Filing a brief in support of	n appeal			
108 690 208 345 Reissue filing fee	121 260 221 130 Request for oral hearing				
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public				
	140 110 240 55 Petition to revive - unavoid	 			
SUBTOTAL (1) (\$) 740.00	141 1,210 241 605 Petition to revive - unintent	ional			
2. EXTRA CLAIM FEES	142 1,210 242 605 Utility issue fee (or reissue	,			
Fee from Extra Claims below Fee Paid	143 430 243 215 Design issue fee	0.00			
Total Claims 21 -20** = 1 x 18 = 18	144 580 244 290 Plant issue fee	0.00			
Independent 5 - 3** = 2 x 84 = 168	122 130 122 130 Petitions to the Commission	ner			
Multiple Dependent =0	123 50 123 50 Petitlons related to provisk	nal applications 0.00			
**or number previously paid, if greater, For Reissues, see below	126 240 126 240 Submission of Information	Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Pee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent ass property (times number of	ignment per properties)			
103 18 203 9 Claims in excess of 20	146 690 246 345 Filling a submission after fill (37 CFR § 1.129(a))	nal rejection			
102 78 202 39 Independent claims in excess of 3	149 690 249 345 For each additional inventi	on to be			
104 260 204 130 Multiple dependent claim, if not paid	examined (37 CFR § 1.129	(b))			
109 78 209 39 ** Reissue Independent claims over original patent	Otherfee (specify)				
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	Otherfee (specify)				
SUBTOTAL (2) (\$) 186.00	Reduced by Basic Filing Fee Paid SUBTO	AL (3) (\$) 920.00			
SUBMITTED BY Complete (if applicable)					
Registration No. 74 April 2017 029 2127					
	CHELYI L. DCCACI (Autometragemy 1991)				
Signature Charul Z. R	P B 1 1 Date	<u> </u>			

WARNING:

Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ->	+	
------------------------------------------------	---	--

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION

Attorney Docket No. 4573.US.C6 First Inventor or Application Identifier Jeffrey C. Hunt

TRANSMITTAL Title Industrial Annough (3-21-3) to Fullian Immunodefficiency Virus GP41 Protein					
(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) Express Mail Label No. EL507386035US					
	APPLICATION ELEMENTS hapter 600 concerning utility patent application contents.	Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC, 20231			
1. X (s (s (s (p	Fee Transmittal Form (e.g., PTO/SB/17) Submit an original and a duplicate for fee processing) pecification [Total Pages 41] pecification [Total Pages 41] Descriptive title of the Invention Cross References to Related Applications Statement Regarding Fed sponsored R & D Reference to Microfiche Appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure rawing(s) (35 U.S.C. 113) [Total Sheets 6] Declaration [Total Pages 2] Newly executed (original or copy) X Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).	5. Microfiche Computer Program (Appendix) 6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 7. X Assignment Papers (cover sheet & document(s)) 8. 37 C.F.R.§3.73(b) Statement Power of (when there is an assignee) Attorney 9. English Translation Document (if applicable) 10. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 11. Preliminary Amendment 12. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	tijon		
IF ONE FILE	ALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT ED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28), ONTINUING APPLICATION, check appropriate box, and supp	by the requisite information below and in a preliminary amendment:			
Continuation Divisional Continuation-in-part (CIP) of prior application No: 08/856,155 Prior application information: Examiner Brumback, B. Group / Art Unit: 1642 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an eath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.					
	17. CORRESPONDEN	CE ADDRESS			
☐ Custon	ner Number or Bar Code Labe I (Insert Customer No. or Attach	or 🏻 Correspondence address below bar code label here)			
Name	Cheryl L. Becker				
Addmas	Abbott Laboratories D-377, AP6D				
Address	100 Abbott Park Road				
City	Abbott Park State IL	Zip Code 60064			
Country		7-938-3137 Fax 847-938-2623			
Name (Print/Type) Cheryl L. Becker Registration No. (Attorney/Agent) 35,441					
Signatur	Cheryt E. Beeker	(Page 25 42)			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.